Fineline Cube

Follow:
14486 Articles
Cedicine Biotech's Umbilical Cord Blood Mononuclear Cell Injection Gains CDE Approval for Clinical Trial
CompanyDrug

Cedicine Biotech’s Umbilical Cord Blood Mononuclear Cell Injection Gains CDE Approval for Clinical Trial

Alphamab Oncology's JSKN003 Granted FDA Orphan Drug Designation for Gastric and Gastroesophageal Junction Cancer
CompanyDrug

Alphamab Oncology’s JSKN003 Granted FDA Orphan Drug Designation for Gastric and Gastroesophageal Junction Cancer

Pierre Fabre's Braftovi Approved in China for BRAF V600E-mutant Metastatic Colorectal Cancer
CompanyDrug

Pierre Fabre’s Braftovi Approved in China for BRAF V600E-mutant Metastatic Colorectal Cancer

Henlius Biotech's HLX14 Recommended for EU Approval by EMA's CHMP
CompanyDrug

Henlius Biotech’s HLX14 Recommended for EU Approval by EMA’s CHMP

Fosun Pharma Secures Licensing Rights for AR1001 in Alzheimer's Treatment
CompanyDeals

Fosun Pharma Secures Licensing Rights for AR1001 in Alzheimer’s Treatment

Boehringer Ingelheim and Re-Vana Partner to Develop First-in-Class Ocular Therapies
CompanyDeals

Boehringer Ingelheim and Re-Vana Partner to Develop First-in-Class Ocular Therapies

Tigermed Acquires Japan's Micron CRO to Expand Imaging Expertise in Asia-Pacific
CompanyDeals

Tigermed Acquires Japan’s Micron CRO to Expand Imaging Expertise in Asia-Pacific

Eli Lilly's Mounjaro Approved by China's NMPA for Type 2 Diabetes Treatment with Insulin
CompanyDrug

Eli Lilly’s Mounjaro Approved by China’s NMPA for Type 2 Diabetes Treatment with Insulin

Antengene's XPOVIO Approved for New Multiple Myeloma Indication by China's NMPA
CompanyDrug

Antengene’s XPOVIO Approved for New Multiple Myeloma Indication by China’s NMPA

Shanghai Biomedicine M&A Fund Acquires Stake in MicroPort via Share Transfer Agreement
CompanyDeals

Shanghai Biomedicine M&A Fund Acquires Stake in MicroPort via Share Transfer Agreement

AstraZeneca Restructures Biopharm Business to Strengthen Autoimmune and Respiratory Therapies
Company

AstraZeneca Restructures Biopharm Business to Strengthen Autoimmune and Respiratory Therapies

Wuxi Apptec Reports Strong Q2 2025 Results with 20.6% Revenue Growth
Company

Wuxi Apptec Reports Strong Q2 2025 Results with 20.6% Revenue Growth